Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021
VC Investment Tops 2020 Level, IPO Value Surges
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.
